Priyanka P Pramanik1, Hemant A Parmar2, Aaron G Mammoser3, Larry R Junck3, Michelle M Kim1, Christina I Tsien1, Theodore S Lawrence1, Yue Cao4. 1. Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. 2. Department of Radiology, University of Michigan, Ann Arbor, Michigan. 3. Department of Neurology, University of Michigan, Ann Arbor, Michigan. 4. Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; Department of Radiology, University of Michigan, Ann Arbor, Michigan; Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan. Electronic address: yuecao@med.umich.edu.
Abstract
PURPOSE: Use of conventional magnetic resonance imaging (MRI) for target definition may expose glioblastomas (GB) to inadequate radiation dose coverage of the nonenhanced hypercellular subvolume. This study aimed to develop a technique to identify the hypercellular components of GB by using high b-value diffusion-weighted imaging (DWI) and to investigate its relationship with the prescribed 95% isodose volume (PDV) and progression-free survival (PFS). METHODS AND MATERIALS: Twenty-one patients with GB underwent chemoradiation therapy post-resection and biopsy. Radiation therapy (RT) treatment planning was based upon conventional MRI. Pre-RT DWIs were acquired in 3 orthogonal directions with b-values of 0, 1000, and 3000 s/mm(2). Hypercellularity volume (HCV) was defined on the high b-value (3000 s/mm(2)) DWI by a threshold method. Nonenhanced signified regions not covered by the Gd-enhanced gross tumor volume (GTV-Gd) on T1-weighted images. The PDV was used to evaluate spatial coverage of the HCV by the dose plan. Association between HCV and PFS or other clinical covariates were assessed using univariate proportional hazards regression models. RESULTS: HCVs and nonenhanced HCVs varied from 0.58 to 67 cm(3) (median: 9.8 cm(3)) and 0.15 to 60 cm(3) (median: 2.5 cm(3)), respectively. Fourteen patients had incomplete dose coverage of the HCV, 6 of whom had >1 cm(3) HCV missed by the 95% PDV (range: 1.01-25.4 cm(3)). Of the 15 patients who progressed, 5 progressed earlier, within 6 months post-RT, and 10 patients afterward. Pre-RT HCVs within recurrent GTVs-Gd were 78% (range: 65%-89%) for the 5 earliest progressions but lower, 53% (range: 0%-85%), for the later progressions. HCV and nonenhanced HCV were significant negative prognostic indicators for PFS (P<.002 and P<.01, respectively). The hypercellularity subvolume not covered by the 95% PDV was a significant negative predictor for PFS (P<.05). CONCLUSIONS: High b-value DWI identifies the hypercellular components of GB and could aid in RT target volume definition. Future studies will allow us to investigate the role of high b-value DWI in identifying radiation boost volumes and diagnosing progression.
PURPOSE: Use of conventional magnetic resonance imaging (MRI) for target definition may expose glioblastomas (GB) to inadequate radiation dose coverage of the nonenhanced hypercellular subvolume. This study aimed to develop a technique to identify the hypercellular components of GB by using high b-value diffusion-weighted imaging (DWI) and to investigate its relationship with the prescribed 95% isodose volume (PDV) and progression-free survival (PFS). METHODS AND MATERIALS: Twenty-one patients with GB underwent chemoradiation therapy post-resection and biopsy. Radiation therapy (RT) treatment planning was based upon conventional MRI. Pre-RT DWIs were acquired in 3 orthogonal directions with b-values of 0, 1000, and 3000 s/mm(2). Hypercellularity volume (HCV) was defined on the high b-value (3000 s/mm(2)) DWI by a threshold method. Nonenhanced signified regions not covered by the Gd-enhanced gross tumor volume (GTV-Gd) on T1-weighted images. The PDV was used to evaluate spatial coverage of the HCV by the dose plan. Association between HCV and PFS or other clinical covariates were assessed using univariate proportional hazards regression models. RESULTS: HCVs and nonenhanced HCVs varied from 0.58 to 67 cm(3) (median: 9.8 cm(3)) and 0.15 to 60 cm(3) (median: 2.5 cm(3)), respectively. Fourteen patients had incomplete dose coverage of the HCV, 6 of whom had >1 cm(3) HCV missed by the 95% PDV (range: 1.01-25.4 cm(3)). Of the 15 patients who progressed, 5 progressed earlier, within 6 months post-RT, and 10 patients afterward. Pre-RT HCVs within recurrent GTVs-Gd were 78% (range: 65%-89%) for the 5 earliest progressions but lower, 53% (range: 0%-85%), for the later progressions. HCV and nonenhanced HCV were significant negative prognostic indicators for PFS (P<.002 and P<.01, respectively). The hypercellularity subvolume not covered by the 95% PDV was a significant negative predictor for PFS (P<.05). CONCLUSIONS: High b-value DWI identifies the hypercellular components of GB and could aid in RT target volume definition. Future studies will allow us to investigate the role of high b-value DWI in identifying radiation boost volumes and diagnosing progression.
Authors: Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang Journal: J Clin Oncol Date: 2010-03-15 Impact factor: 44.544
Authors: Whitney B Pope; James Sayre; Alla Perlina; J Pablo Villablanca; Paul S Mischel; Timothy F Cloughesy Journal: AJNR Am J Neuroradiol Date: 2005 Nov-Dec Impact factor: 3.825
Authors: Laurent Salphati; Timothy P Heffron; Bruno Alicke; Merry Nishimura; Kai Barck; Richard A Carano; Jonathan Cheong; Kyle A Edgar; Joan Greve; Samir Kharbanda; Hartmut Koeppen; Shari Lau; Leslie B Lee; Jodie Pang; Emile G Plise; Jenny L Pokorny; Hani Bou Reslan; Jann N Sarkaria; Jeffrey J Wallin; Xiaolin Zhang; Stephen E Gould; Alan G Olivero; Heidi S Phillips Journal: Clin Cancer Res Date: 2012-09-19 Impact factor: 12.531
Authors: Anca L Grosu; Wolfgang A Weber; Martina Franz; Sibylle Stärk; Morand Piert; Reinhard Thamm; Hartmut Gumprecht; Markus Schwaiger; Michael Molls; Carsten Nieder Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-01 Impact factor: 7.038
Authors: E E Graves; S J Nelson; D B Vigneron; C Chin; L Verhey; M McDermott; D Larson; P K Sneed; S Chang; M D Prados; K Lamborn; W P Dillon Journal: Neurosurgery Date: 2000-02 Impact factor: 4.654
Authors: Irwin H Lee; Morand Piert; Diana Gomez-Hassan; Larry Junck; Lisa Rogers; James Hayman; Randall K Ten Haken; Theodore S Lawrence; Yue Cao; Christina Tsien Journal: Int J Radiat Oncol Biol Phys Date: 2008-10-01 Impact factor: 7.038
Authors: Robert H Press; Jim Zhong; Saumya S Gurbani; Brent D Weinberg; Bree R Eaton; Hyunsuk Shim; Hui-Kuo G Shu Journal: Neurosurgery Date: 2019-08-01 Impact factor: 4.654
Authors: Daekeun You; Michelle M Kim; Madhava P Aryal; Hemant Parmar; Morand Piert; Theodore S Lawrence; Yue Cao Journal: J Med Imaging (Bellingham) Date: 2017-11-15
Authors: Jann N Sarkaria; Leland S Hu; Ian F Parney; Deanna H Pafundi; Debra H Brinkmann; Nadia N Laack; Caterina Giannini; Terence C Burns; Sani H Kizilbash; Janice K Laramy; Kristin R Swanson; Timothy J Kaufmann; Paul D Brown; Nathalie Y R Agar; Evanthia Galanis; Jan C Buckner; William F Elmquist Journal: Neuro Oncol Date: 2018-01-22 Impact factor: 12.300
Authors: John T Lucas; Nick Serrano; Hyun Kim; Xingyu Li; Scott E Snyder; Scott Hwang; Yimei Li; Chia-Ho Hua; Alberto Broniscer; Thomas E Merchant; Barry L Shulkin Journal: J Neurooncol Date: 2017-01-11 Impact factor: 4.130
Authors: John T Lucas; David A Cooper; Scott Hwang; Christopher Tinkle; Xingyu Li; Yimei Li; Brent Orr; Thomas E Merchant; Alberto Broniscer Journal: Int J Radiat Oncol Biol Phys Date: 2017-05-04 Impact factor: 7.038